ALK and neuroblastoma: Cox regression analysis identified that, even after accounting for the effects of stage, high HDAC8 co-expressed with ALK is a significant risk factor for poor outcomes in neuroblastoma patients (Supplementary Table 3), further supporting the investigation of combining an HDAC8 inhibitor with an ALK inhibitor for neuroblastoma treatment.